taiho pharma r&dmajor progresses since “r&d meeting” on oct. 10, 2020 development...

|Taiho R&D Introduction| 2020/09/29 |1

TAIHO PHARMA R&D

Sep. 29, 2020Taiho Pharmaceutical Co., Ltd.

Copyright © Taiho Pharmaceutical Co., Ltd.


Disclaimer

• This material contains forward-looking statements regarding the financial conditions, results of operations andbusiness activities of Otsuka and its subsidiaries (collectively the “Otsuka Group”). All forward-lookingstatements, due to their inherent nature, will be influenced by future events and developments for which theoccurrence is uncertain, and therefore involve risks and uncertainties. Otsuka cautions you in advance thatactual financial conditions, results of operations and business activities could differ materially from thosediscussed in the forward-looking statements.

• Otsuka disclaims any intention or obligation to update or revise any forward-looking statements whether as aresult of new information, future events, or otherwise.

• Furthermore, this material contains statements and information regarding corporate entities other than thosebelonging to the Otsuka Group, which have been compiled from various publically-available sources. Otsuka hasnot verified any of such statements or information and does not provide any guarantees with regard to theiraccuracy and relevance.

• The IQVIA, Euromonitor and other reports described herein (the “Reports”) represent data, research opinions orviewpoints published as part of a syndicated subscription service and are not representations of fact. TheReports speak as of their original publication dates (and not as of the date of this material), and the opinionsexpressed in the Reports are subject to change without notice.

• This material contains information on pharmaceuticals (including compounds under development), but thisinformation is not intended to make any representations or advertisements regarding the efficacy oreffectiveness of these preparations nor provide medical advice of any kind.


Agenda

R&D Activity SummaryMajor Progresses since “R&D Meeting” on Oct. 10, 2019Development PipelineOpen Innovation and Venture Investment

Development Pipeline UpdatesFutibatinib(TAS-120)TAS-115

Drug Discovery Research Updates Expansion of Cysteinomix (from Kinases to RAS Drug Discovery) Brain Metastasis Drug Discovery (Partnering with MD Anderson Cancer Center）


Agenda





Taiho Pharma R&D: Major Progresses since last R&D Meeting

Basic research

collaboration

Small molecules against several drug targets including KRAS

Initiate collaboration with Astex and MSD Jan. 6, 2020News Release

In-license Zimberelimab(AB122; anti-PD-1 antibody)

Obtain development and commercialization rights of an anti-PD-1 antibody, AB122 in Japan and certain other territories in Asia (excluding China) from Arcus Biosciences

Feb. 27, 2020News Release

Basicresearch

collaborationBrain metastasis drug discovery Partner with MD Anderson Cancer Center Sep. 24, 2020

News Release

Clinical development

Futibatinib(TAS-120; FGFR inhibitor)

Publish the result of interim analysis of a Phase 2 study in patients with intrahepatic cholangiocarcinoma

ASCO2020Oral Presentation


Strategic Oncology Collaboration Targeting KRAS OncogeneNews Release


Research Collaboration with MD Anderson Cancer CenterTaiho Pharma News Releaseon Sep. 24, 2020

2015～

Covalent BindersCysteinomix

2010～

SBDD/FBDD2009～

Kinase Inhibitors2009～

Natural Product2014～

UFT TS-1 Lonsurf

ClinicalApproved

Nucleic Acids1993～

DNA-encoded Library

2016～

Brain MetastasisBrain Cancer

2017～

TAS-114

Technology Enabled Drug Discovery in Taiho

TAS0728TAS-120 TAS5315 TAS6417

TAS3681

TAS1440

TAS-116

TAS-117

TAS-119

TAS-115

RAS2012～2019～

8


Development Pipeline (As of Jun. 30, 2020)

TAS-115Multi tyrosine kinase inhibitorProstate Cancer etc.JPN

TAS-114dUTPase/DPD inhibitorNSCLCJPN, US, EU

TAS-116HSP90 inhibitorGIST etc.JPN

TAS-120FGFR inhibitoriCCA, Breast Cancer etc.JPN, US, EU

Pro-NETUNK1RAChemotherapy-induced Nausea & VomitingJPN In-licensed from Helsinn

ET-743DNA minor groove binderOvarian CancerJPNIn-licensed from PharmaMar

TAS-117Allosteric AKT inhibitorSolid TumorJPN

TAS3681Novel AR antagonistProstate CancerUS, EU

TAS6417/CLN-081EGFR inhibitorOut-licensed to Cullinan Pearl

TAS-119

TAC-302Neuroprotective AgentDetrusor low activityOveractive BladderJPNIn-licensed from Meiji

TAS-303Selective NA Re-uptake inhibitorStress Urinary IncontinenceJPN

TAS-205Prostaglandin D2 synthase inhibitorDuchenne Muscular DystrophyJPN

TAS5315BTK inhibitorRheumatoid ArthritisJPN

TAS-115Multi tyrosine kinase inhibitorIdiopathic pulmonary fibrosisJPN

Phase 1 Phase 2 Phase 3

Molecular targeting

Others

Molecular targeting

Supportive care

Cytotoxic

Oncology

Other Disease Area

TAS1440LSD1 inhibitorAMLUS

Immunooncology

TAS0313Peptide VaccineUrothelial CancerJPN

TAS0728Her2 inhibitorSolid TumorUS, EU

AB928A2AR/A2BR AntagonistIn-licensed from Arcus Biosciences

AB122PD-1 inhibitorIn-licensed from Arcus Biosciences

Aurora A inhibitorOut-licensed to VITRAC Therapeutics

Preparing Clinical Development in Japan/Asia (ex. China)

TAS0953/HM06

Co-developmentwith Helsinn

RET inhibitor

Pre-clinical

IND

Out-licensed to VITRAC Therapeutics

Stage up to Phase 1Developing by Astex

Stage up to Phase 1 Developing byCullinan Pearl

Acquired development and commercialization rights

Started Breast Cancer study

TAS-118Development discontinued

Update from Jun. 30, 2019


Access to Highly “Innovative” Drugs : A Multifaceted Approach

Access to Innovative Drugs through Venture Investment

Late

Early

REMIGESVENTURES

TAIHOVENTURES

Wide range of disease areas

Tsukuba Research Center

Mainly Oncology

Obtaining innovative technologies and innovative development concepts not available in-house.

Example) Types of Drugs Small Molecule Medium Sized Molecule Antibody Vaccine Cell Therapy

Example) Disease Area Oncology Immunology/Allergy

Urology

Cancer (Innovative Treatments)

Rare Diseases

Development Stage Business Development

Oncology, Immunology/Allergy, Urology

TAIHO INNOVATIONSOncology, Immunology/Allergy,

Urology

http://www.google.co.jp/url?url=http://www.kms.ac.jp/%7Ephysiol1/researchallse5fu.html&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwj0k_jK07PLAhVM6WMKHSABAyIQwW4IFjAA&usg=AFQjCNECVltPMOJAq_T55hoIi2vILK9HYA

http://www.google.co.jp/url?url=http://www.kms.ac.jp/%7Ephysiol1/researchallse5fu.html&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwj0k_jK07PLAhVM6WMKHSABAyIQwW4IFjAA&usg=AFQjCNECVltPMOJAq_T55hoIi2vILK9HYA

http://www.google.co.jp/url?url=http://www.wdb.com/student/ill/11.html&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjx4fLx0rPLAhUN9mMKHb5MA8UQwW4IIDAF&usg=AFQjCNFhxrhiUdRCUhiFK9bQ0sVOg_Z8pg

http://www.google.co.jp/url?url=http://www.wdb.com/student/ill/11.html&rct=j&frm=1&q=&esrc=s&sa=U&ved=0ahUKEwjx4fLx0rPLAhUN9mMKHb5MA8UQwW4IIDAF&usg=AFQjCNFhxrhiUdRCUhiFK9bQ0sVOg_Z8pg


Taiho Ventures’ Portfolio Companies

Immuno-Oncology

Checkpoint inhibitor TCR-T cell therapy T-cell engager TME immune stimulant

(RCUS) (NXTC) (HARP)

Oncology

RNA epigenetics Cancer resistance DNA damage response Oncogenic driver

Microbiome

As of Aug. 31, 2020

(ORIC)Spin-out TAS6417 to

Cullinan Pearlto accelerate its clinical

development

Taiho Ventures will have a first right to negotiate for an exclusive license

related to the new oncology programs


Arcus Biosciences Anti-PD-1 antibody Zimberelimab (AB122): Obtained Rights to Develop and Commercialize in Japan and Certain Other Territories in Asia

Obtain development and commercialization rights of an Adenosine Receptor Antagonist

Preparing clinical development in Japan/Asia

Obtain development and commercialization rights of an anti-PD-1 antibody

Preparing clinical development in Japan/Asia

Taiho Pharma News Releaseon Feb. 27, 2020


Agenda





Clinical Pipeline Update

Futibatinib (TAS-120)- Covalent FGFR inhibitor- Potential Best-in-class drug- Indications (under development) : Intrahepatic

cholangiocarcinoma, Breast cancer, Gastric cancer, and others

TAS-115- Multi tyrosine kinase inhibitor- Potential Best-in-class drug- Indications (under development) : Idiopathic pulmonary fibrosis,

Osteosarcoma, and others


FUTIBATINIB（TAS-120）



Key Profiles of Futibatinib

FGFR fusion gene

Growth factor

Tumorgrowth

Tumorgrowth

Cancer cell

Inhibits all 4 family receptors (FGFR1-4);Expected to show effects in cancer typesthat does not respond to other drugs

The only covalently-binding FGFR inhibitor inclinical development stage

Expected to be effective in patients whohave acquired resistance mutations to otherdrugs

Expected to have high antitumor activitywith few side effects

Futibatinib


Overcoming Acquired Resistance in Patients with FGFR2 Gene Fusion

AACR Annual Meeting 2019, Abstract CT239, L. Goyal et al.

Recurrence 1 year after response to the FGFR inhibitor (BGJ398)

Response and stable disease on futibatinibfor over one year

At the time of recurrence, a resistance mutation appeared in the blood, but the clone disappeared after administration of futibatinib

Many more cases of response with futibatinib after recurrence with other FGFR inhibitors.


Futibatinib Demonstrates Meaningful Clinical Benefit in iCCA Patients with FGFR2 Gene Fusions

Completed enrollment of Global Phase 2 study aiming early approval.Currently Planning Phase 3 study for 1st line iCCA.

ASCO Annual Meeting 2020, Abstract 108 Lipika Goyal et al.

• Response rate：37.3％，Disease control rate：82.1%• Progression-free survival (median): 7.2 months

iCCA: intrahepatic cholangiocarcinoma


Futibatinib: Adverse Events

ASCO Annual Meeting 2020, Abstract 108 Lipika Goyal et al.

MedDRA (v18.1) preferred termAll patients (N=67), n (%)

Grade 1 Grade 2 Grade 3 TotalPatients with at least one AE 6 (9.0) 23 (34.3) 38 (56.7) 67 (100)Hyperphosphatemia 4 (6.0) 32 (47.8) 18 (26.9) 54 (80.6)Diarrhea 18 (26.9) 7 (10.4) 0 25 (37.3)Dry mouth 19 (28.4) 3 (4.5) 0 22 (32.8)Alopecia 15 (22.4) 5 (7.5) 0 20 (29.9)Dry skin 13 (19.4) 5 (7.5) 0 18 (26.9)Fatigue 10 (14.9) 2 (3.0) 4 (6.0) 16 (23.9)Aspartate aminotransferase increased 6 (9.0) 1 (1.5) 6 (9.0) 13 (19.4)Dry eye 10 (14.9) 2 (3.0) 1 (1.5) 13 (19.4)Dysgeusia 9 (13.4) 4 (6.0) 0 13 (19.4)Alanine aminotransferase increased 3 (4.5) 5 (7.5) 4 (6.0) 12 (17.9)Constipation 8 (11.9) 4 (6.0) 0 12 (17.9)Palmar-plantar erythrodysesthesiasyndrome 4 (6.0) 7 (10.4) 1 (1.5) 12 (17.9)

Nail disorder 8 (11.9) 3 (4.5) 0 11 (16.4)Stomatitis 6 (9.0) 3 (4.5) 2 (3.0) 11 (16.4)


Expansion to Other Types of Cancers as a Single Agent

ESMO 2017 Congress, Abstract 372 PD, Y. Kuboki et al.

In the Phase 1 study, multiple cases of tumor reduction in other cancer types (including gastric cancer) have been observed.

Currently planning multiple Phase 2 studies.


Tumor Agnostic Phase 2 Study is Ongoing

Cohort AAdvanced/metastatic solid tumors with FGFR1–4rearrangements* (n=60)

Cohort BAdvanced/metastatic gastric or GEJ cancer with FGFR2 amplification (n=35)

Cohort CMLN with FGFR1 rearrangements (n=20)

Futibatinib

20 mg QD orally in 28-day cycles

https://clinicaltrials.gov/ct2/show/NCT04189445

Primary endpointCohort A, B：Objective response rateCohort C：Complete response rate

GEJ: Gastroesophageal junctionMLN: Myeloid or lymphoid neoplasms* Brain tumors and iCCA are excluded.


Futibatinib: Development Strategy for Combination Therapy Recent studies have revealed that FGFRs plays many roles including tumor microenvironment and drug

resistance. Taiho currently aims to achieve clinical efficacy in combination therapies.

Tumor microenvironment

FGFR inhibitors reduce the number of myeloid-derived suppressor cells (MDSC) via fibroblasts and attenuate tumor immune resistance.

Anticancer drug resistance

FluvestrantInhibition

HR positivebreast cancer

K-Ras mutant lungcancer

MEK inhibitor

ERK inhibitor

FGFR

inhibition

Futibatinib

Resistance

Combination study of futibatinib with IO drugs planned.

Combination studies of futibatinib with various anticancer agents planned (ongoing, in part).

Cell Physiol Biochem. 2014;33:633-45 L. Liu et al.

ER responsive element

ERα ERαE2 E2

PI3K

AKT

RAS

RAF

MEK

ERKT cellCAF* Tumor

IO-drug(Anti-PD-1 etc.)

T-cell activation

inhibition

MDSC

Activates immunosuppressive

cells

Futibatinib

Cancer cells make an environment to escape the immune

system

attack

*CAF:cancer-associated fibroblast

By combination with futibatinib,

IO-drug’s efficacy will increase

（Hypothesis） Resistance


Futibatinib (TAS-120)：Ongoing Studies of Combination Therapy

• TAS-120 monotherapy/TAS-120+fulvestrant– Phase 2 study for FGFR mutated Breast Cancer

• TAS-120+pembrolizumab– Phase 1 study for FGFR mutated Solid Tumor

• TAS-117+TAS-120– Phase 1/2 study for FGFR mutated Solid Tumor

(NCT04024436)

(JapicCTI-195063)

(JapicCTI-194864)


TAS-115(PAMUFETINIB) (MULTI TYROSINE KINASE INHIBITOR)



Idiopathic Pulmonary Fibrosis（IPF）

Annual incidence and prevalence of IPF【Japan】Approximately 14,000 ptsAnnual incidence 2.23 patients/100KPrevalence 10.0 patients/100K

【US/EU】Annual incidence 4.6-8.8 patients/100KPrevalence 14.0-27.9 patients/100K

Idiopathic pulmonary fibrosisA type of Idiopathic Interstitial Pneumonia defined in the National Registry of Designated Intractable Diseases in Japan Poor prognostic, idiopathic lung disease. Irreversible honeycomb form as a result of severe fibrosis Dyspnea and progressive decline in respiratory function are known as the typical symptom

Lung diffusion capacity is also declined in IPF patients

IPF Lung

Dry cough：Dyspnea

Fibrosis

Treatment option for IPF is limited. Nintedanib and pirfenidone are approved drug recommended in the International Treatment Guideline.

Median overall survival in IPF is reported as approximately 3 years after diagnosis.

Lung in healthy people

Eur Respir Rev. 2012; 21: 141-6. RM. du Bois

Am J Respir Crit Care Med 2014; 190: 773-9 M. Natsuizuka et al.

Chest 2010; 137: 129-37 ER. Fernández Pérez et al.Thorax 2006; 61: 980-5 J. Gribbin et al. Am J Respir Crit Care Med 2006; 174: 810-6 G. Raghu et al.


【IPF】 Efficacy: Significant Suppression of FVC Decline in Phase 2 Study

FVC；71.6%

FVC；75.1%

We are currently planning a Phase 3 study.American Thoracic Society 2020 International Conference. Abstract 4547, Arai N et al.

N=45

(週)

ERS International Congress 2019, Abstract PA1296, T. Ogura et al.

Pre-TAS-115 treatment TAS-115 treatment period

－ After nintedanib－ After pirfenidon－ No prior treatment

Remarkable responder


Phase 3 Study of TAS-115 in Patients with Osteosarcoma has Started

Treatments for unresectable / metastatic osteosarcoma are limited and medical needs are high.

J Orthop Sci. 2017;22:755-64 Ogura K et al.

TAS-115 has a unique kinase inhibition spectrum and high antitumor activity against osteosarcoma and bone metastasis.

Efficacy of TAS-115 for OsteosarcomaOsteosarcoma

• Bone sarcomas include osteosarcoma,chondrosarcoma, Ewing's sarcoma, and giantcell tumor of bone.

• The annual incidence of osteosarcoma inJapan is said to be 200 to 300. Many casesoccur in teens to 20s.

FEBS Open Bio. 2020;10:767-779. Yasuda N et al.

Control

TAS-115 50mg/kg

TAS-115 200mg/kg

day14day7 day21


Phase 1 Study of TAS-115 in Patients with Osteosarcoma (20 cases)

In some cases, the treatment period with TAS-115 is longer than that of the previous treatment. We have started a Phase 3 study.

Naka N et al., The 2nd Annual Meeting of Japanese Association of Sarcoma Treatment and Research 2019, P3-3

Data cut-off date is Aug 19, 2018

Pre-TAS-115 treatment TAS-115 treatment period


Phase 3 Study DesignR cohort

P cohort

≧15 years old Osteosarcoma Refractory or intolerance to MAP regimen or

similar ones Unable curative resection due to metastatic

lesion Primary lesion has been removed

completely

R

TAS-115

Placebo

target sample size：60

7-15 years old Osteosarcoma Refractory or intolerance to MAP regimen or

similar ones Unable curative resection due to metastatic

lesion Body weight is over 30 kg

TAS-115

TAS-115PD

JapicCTI-205335MAP: Methotrexate+Doxorubicin+CisplatinPD: Progressive Disease

Primary endpoint：Progression-free survival based on blinded central radiological review, Overall survivalExpected duration of study：June 2020 - June 2023

target sample size：6


Agenda




2015～SBDD/FBDD

2009～



UFT TS-1 Lonsurf

ClinicalApproved


DNA-encoded Library

2016～


2017～

TAS-114


TAS0728TAS5315 TAS6417

TAS3681

TAS1440

TAS-116

TAS-117

TAS-119

TAS-115

RAS2012～2019～


2010～TAS-120

31


Expansion of Cysteinomix~from Kinases to RAS Drug Discovery~



Cysteinomix Drug Discovery Platform

Covalent Binding Drug

Target Protein（Cysteinome）

• CysteinomeDruggable proteins that have reactive amino acid residues (ex. Cys) located inside or adjacent to the binding sites of small to medium-sized molecules

• Covalent Binding DrugsDrugs that specifically capture reactive amino acid residues (ex. Cys) by forming covalent bonds


MS Screening Assay

Target Cysteinome + covalent binder

Target CyseinomeIdentification of covalent binding adducts

• CysteinomixTaiho’s proprietary technology platform to identify drugs that specifically form a covalent bond with the target cysteinome

Covalent binder library

Target cysteinome

Cysteine



Futibatinib：The World’s First Covalent FGFR Inhibitor

Futibatinib(TAS-120)

Futibatinib conc.100nM

KinomeScan456 kinase

FGFR1, 2, 3, and 4 were specifically inhibited

Futibatinib was found to show potent and selective inhibition of FGFR1, 2, 3, and 4 by forming a covalent bond with the targeted Cys in FGFR1, 2, 3, and 4→ Currently in Phase 2 and aim to achieve early approval.

Figure 4B

FGFR: Fibroblast growth factor receptor

Cancer Discov. 2019;9:1064–79L. Goyal et al.



• Cysteinome Identification PlatformProprietary technology for genome-wide screening of druggable Cysteinome

Cysteinome

Target Cysteinome

Genome Wide Search of Targetable Cysteinome

Experimentally Validate the Reactivity of Teget Cysin Cysteinome

Proc. Natl Acad. Sci. USA 2014; 111: 8895-8900. John C Hunter et al.

Drug Discov Today. 2018; 23: 727-735. Zheng Zhao et al.Nat Rev Drug Discov. 2012; 11: 384-400. Cheryl H Arrowsmith et al.

Disease related geneome(Kinome, Epigenome, GTPase family etc.)


Cysteinomix Drug Discovery Targeting Small GTPase Family• Small GTPase family (160)• Protein kinase family (518)

The 188 kinases and 217 locations are shown in different colors and symbols

188518

29160

Proc. Natl Acad. Sci. USA 2014; 111: 8895-8900. John C Hunter et al.Drug Discov Today. 2018; 23: 727-735. Zheng Zhao et al.

Cysteinome Cysteinome

FGFR (TAS-120)

BTK (TAS5315)

EGFR exon20 (TAS6417)

HER2 (TAS0728)

KRAS G12C


Drug Discovery Targeting RAS Oncogene

Mutant RAS driven cancers are high unmet medical needsFrequently mutated in deadly cancers (lung, pancreatic, colon, etc.)Remained as undruggable targets despite 30 years challengesInvolved in highly complicated intracellular protein-protein interactions

Normal Cancer

Nat Rev Cancer 2018, 18, 767–777. Li, S., Balmain, A. & Counter, C.M


Oncogenic KRAS Mutations Are Highly Valuable Targets

Pancreatic

Colorectal

Adenocarcinoma

KRAS G12 mutation

Incidence of KRAS Mutations in Three Human Cancers

Percentages of KRAS mutations that are in codon 12 by tissue type for pancreatic, colorectal and lung adenocarcinoma

Nat Rev Drug Discov 2018; 19: 533–552. Amanda R. Moore et al.

Cancer Cell. 2014; 25: 272-281. Andrew G. Stephen et al.

HN CH C

CH2

O

SHCysteine

KRAS G12C

HN CH C

CH2

O

CO OAspartic acid

KRAS G12D KRAS G12V

HN CH C

CH

O

CH3H3CValine


Cysteinomix Screening of KRAS G12C Covalent Binders

KRAS G12C（Cancer Cell）Target Cysteinome

KRAS G12C – Compound X

KRAS wild-type (Normal Cell)Off target

Discovery of covalent bindingKRAS modulators

High speed MS binding assay

Covalent binder library


Strategic Oncology Collaboration Targeting KRAS Oncogene

41

News Release

2015～


2010～

SBDD/FBDD2009～



UFT TS-1 Lonsurf

ClinicalApproved


DNA-encoded Library

2016～


2017～

TAS-114


TAS0728TAS-120 TAS5315 TAS6417

TAS3681

TAS1440

TAS-116

TAS-117

TAS-119

TAS-115

RAS2012～2019～

42


Brain Metastasis and Brain Cancers



Primary Site Occupancy(%)

Lung Cancer 50-60%Breast Cancer 20-30%

Melanoma 5-10%Gastric, Esophageal,

Prostate, Ovarian CancerIn total5-10%

Advance in Cancer Therapy Leads to Increased Brain Metastasis

Frequency of brain metastasis according to primary site

Newly diagnosed cases of brain metastases

US：200,000 patients/yearJapan：～80,000 patients/year

OA Mol Oncol. 2013;1(1) A Bollig-Fischer et al. NCCN Guidelines Version 3.2020 (Central Nervous System Cancers)Practical Guidelines for Neuro-Oncology 2019, The Japan Society for Neuro-Oncology

Metastatic Brain Tumor Brain CancersNewly diagnosed cases

US：23,890 patients/year

Prognosis and Treatment（Glioblastoma ）• Glioblastoma is an almost incurable

disease with a median survival of14.6 months, even in patients whocan be treated with standardtreatment.

• Treatment for glioblastoma islimited to temozolomide andbevacizumab.


Our Strategy to Tackle Brain Metastasis

Pioneering Basic and Clinical Brain Metastasis Research

Research Collaboration withMD Anderson Cancer Center

Drug Discovery PlatformsTargeting Brain Metastasis

Discovery BrainPenetrant Compounds


Research Collaboration with MD Anderson Cancer Center

Taiho Pharma News Releaseon Sep. 24, 2020

taiho pharma r&dmajor progresses since “r&d meeting” on oct. 10, 2020 development...

Documents